Global biotech leader CSL just bolstered their defenses in the battle against pathogens with the opening of a 140,000 square foot research and development site, dedicated to ushering in a new era of excellence in vaccine development.
“I'm excited by what this facility represents,” said CSL’s newly appointed CEO and Managing Director Paul McKenzie at the Waltham, Massachusetts site’s grand opening.
With its prime location in the innovative greater Boston area, plus state-of-the-art office and lab space, the site further activates the collective power of our people as well as partnerships like our most recent with Arcturus Therapeutics, he shared.
“It’s not just a place of research, but a hub where technological advancements and vaccine design intersect. A place where we can collaborate with like-minded stakeholders all with the shared goal of protecting public health, now and into the future,” McKenzie said.
“The Waltham location provides our scientists with the opportunity to collaborate closely with industry and academic partners, allowing greater access to ongoing innovation and talent,” said Ethan Settembre, Ph.D., Vice President, Research, CSL Vaccines Innovation Unit and site head for this facility.
The site highlights CSL’s expanding global R&D footprint – a footprint that includes more than 2,000 R&D employees in 10 countries, working in integrated teams.
“This world-class facility will provide our talented people with the ideal environment to deliver the breakthroughs that CSL aims to achieve,” said Settembre.
Click here to learn more about the Waltham facility.
